EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes—The Steady Sugar trial

Karen Elkind-Hirsch, Missy Armatta, Corbin Griffen, John B Welsh iD, Edward Veillon, Stacey Guedry, Jill Ballard, Margaret A Crawford, Angelo Monroy, Harsimran Singh, Giacomo Cappon

Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 691-700

DOI: 10.1111/dom.70254 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.11.2025. Verfasst von Karen Elkind-Hirsch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Affairs, Dexcom, Inc., San Diego, California, USA. Hauptthemen laut MEDLINE: Diabetes, Gestational, Blood Glucose Self-Monitoring, Blood Glucose. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Dexcom.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Early detection and management of gestational diabetes mellitus (GDM) benefits both mother and infants. We aimed to compare continuous glucose monitoring (CGM) to routine self‐monitoring of blood glucose (SMBG) in a randomised controlled trial on glycaemic management and pregnancy outcomes in women with GDM diagnosed in gestational Weeks 8–26. Materials and Methods From October 2021 to December 2023, 128 women with GDM were enrolled and 120 completed the trial after 2:1 randomisation to either the intervention (Dexcom G6 CGM, n = 80) or the control group (SMBG 4×/day and monthly blinded CGM [Dexcom G6 Pro], n = 40). Both groups received lifestyle and medication advice based on the CGM interpretation, clinical follow‐up and glucose monitoring until delivery. CGM metrics were evaluated with the automated glucose data analysis (AGATA) toolbox ( https://github.com/gcappon/agata ) and maternal and neonatal outcomes were collected from medical records. Participants completed the CGM Satisfaction survey prior to delivery.

Results

While no significant differences between groups in time spent in the glucose target range (TIR) 63–140 mg/dL (primary outcome) were found ( p = 0.37), the intervention group experienced significantly lower unscheduled caesarean section rates (20.0% vs. 44.4%, p = 0.046, V = 0.19) and preterm deliveries (6.8% vs. 18.4%, p = 0.041, V = 0.19). Neonates experienced lower large‐for‐gestational‐age rates (5.0% vs. 18.4%, p = 0.019, V = 0.22) and neonatal intensive care unit admissions (22.5% vs. 44.7%, p = 0.013, V = 0.23) compared to the control group. Participants in the intervention group reported high CGM satisfaction and endorsed the behavioural and psychosocial benefits.

Conclusions

For women with early GDM, despite no improvement in TIR, CGM improved maternal and neonatal outcomes versus SMBG. The effect may be mediated by improved awareness of glycaemic excursions and by facilitation of treatment regimen adjustments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes, GestationalBlood Glucose Self-MonitoringBlood GlucoseHumansFemalePregnancyAdultInfant, NewbornPregnancy OutcomeGlycemic ControlContinuous Glucose Monitoring

Stichwörter der Autor:innen

continuous glucose monitoring (CGM)gestational diabetespatient reported outcomesrandomised trial

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Clinical Affairs, Dexcom, Inc., San Diego, California, USA.
  • Woman's Diabetes Clinic, Woman's Hospital, Baton Rouge, Louisiana, USA.
  • Maternal-Fetal Department, Woman's Hospital, Baton Rouge, Louisiana, USA.
  • Behavioral Science, Dexcom, Inc., San Diego, California, USA.
  • Department of Information Engineering, University of Padova, Padova, Italy.

ORCID-Profile: John B Welsh

Förderung

  • Dexcom

Zitieren

APA

Elkind-Hirsch, K., Armatta, M., Griffen, C., Welsh, J. B., Veillon, E., Guedry, S., Ballard, J., Crawford, M. A., Monroy, A., Singh, H., & Cappon, G. (2026). Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes—The Steady Sugar trial. Diabetes, Obesity and Metabolism, 28(1), 691-700. https://doi.org/10.1111/dom.70254

Vancouver

Elkind-Hirsch K, Armatta M, Griffen C, Welsh JB, Veillon E, Guedry S, et al. Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes—The Steady Sugar trial. Diabetes, Obesity and Metabolism. 2026;28(1):691-700. doi:10.1111/dom.70254

BibTeX
@article{ElkindHirsch2026,
  author = {Elkind-Hirsch, Karen and Armatta, Missy and Griffen, Corbin and Welsh, John B and Veillon, Edward and Guedry, Stacey and Ballard, Jill and Crawford, Margaret A and Monroy, Angelo and Singh, Harsimran and Cappon, Giacomo},
  title = {Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes—The Steady Sugar trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {1},
  pages = {691--700},
  doi = {10.1111/dom.70254}
}
Kostenlos starten →